Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Arzerra, Kesimpta
Ofatumumab is a monoclonal antibody that targets the CD20 protein found on the surface of B cells, a type of white blood cell. It is used to treat certain types of cancer and multiple sclerosis. By binding to CD20, ofatumumab triggers the destruction of B cells, which can help to control the immune system's overactivity in these conditions.
Used to treat chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and other B-cell malignancies.
Severe infections, including progressive multifocal leukoencephalopathy (PML). Hepatitis B reactivation. Immunization with live or live-attenuated vaccines is not recommended.
Outcome:
Reduced vaccine efficacy, increased risk of infection
Mechanism:
Ofatumumab suppresses the immune system
Outcome:
Increased risk of bleeding
Mechanism:
Both drugs can affect platelet function
Outcome:
Reduced ofatumumab absorption
Mechanism:
Changes in stomach pH
Most likely new formulation: Subcutaneous injection (2025, 80% confidence)
Based on current clinical trial data and usage trends, there is a 70% likelihood of expanded indications for ofatumumab in the next 5 years.
Monoclonal antibody, Antineoplastic, Immunomodulator
Immunoglobulin G1 (IgG1) monoclonal antibody